Cell News and Research

RSS

MiRNA-21 interferes with Herceptin therapy, says study

Overexpression of a specific type of microRNA can derail treatment by disabling an important molecular brake on breast cancer cell proliferation, according to evidence presented by researchers from The University of Texas M. D. Anderson Cancer Center at the American Association for Cancer Research 101st Annual Meeting 2010.

17 Apr 2010

Marker found in iPS cells correlates with levels of pluripotency: Researchers

Researchers in China are reporting that they have found a way to determine which somatic cells -- or differentiated body cells -- that have been reprogrammed into a primordial, embryonic-like state are the most viable for therapeutic applications.

17 Apr 2010

New drug to stop the growth of prostate cancer tumors investigated

The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.

17 Apr 2010

Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH

Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.

17 Apr 2010

Treatment with high dose UDCA no more effective for NASH: German study

Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid is no more effective than placebo in the treatment of non-alcoholic steatohepatitis, the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver.

17 Apr 2010

Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009

Tikcro Technologies Ltd. today reported results for the fourth quarter and year ended December 31, 2009.

17 Apr 2010

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

17 Apr 2010

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

A new study of almost 700 patients from The Mount Sinai Medical Center shows that prostate cancer patients who had robotically assisted prostatectomy enjoyed significant benefits over patients who had a traditional open radical prostatectomy, including decreased surgical and recovery time, less blood loss during surgery and significantly shorter hospital stays.

16 Apr 2010

Research reveals TRPV3 protein as potential new drug target for cancer and skin disorders

New findings about a temperature sensor in the skin could lead to novel approaches to controlling excess hair growth and treating skin cancers.

16 Apr 2010

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

The socioeconomic status of a country has long been considered a potentially significant factor in the availability of high-quality health-care interventions and even a determinant of long-term patient outcomes. A new study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation reports that in Europe, socioeconomic factors have a direct correlation to the rates and outcomes of stem cell transplantation for patients with acute myeloid leukemia (AML).

16 Apr 2010

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Type 1 diabetes is the most common cause of diabetes in children, although it may occur at any age. Also called juvenile diabetes, this pathology usually results from autoimmune destruction of insulin-producing cells of the pancreas.

16 Apr 2010

Pharmacyclics to present on Btk and HDAC programs at AACR 2010

Pharmacyclics, Inc. today announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research 2010 Annual Meeting being held April 17-21 in Washington, DC.

16 Apr 2010

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the Company's New Drug Application (NDA) for the use of Soliris® (eculizumab) as a treatment for patients in Japan with paroxysmal nocturnal hemoglobinuria (PNH).

16 Apr 2010

New study may help devise better treatment strategies for cancer and heart disease

Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer.

16 Apr 2010

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Drug discovery company SCYNEXIS, Inc. today presented data supporting an impressive resistance profile for SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection. In the study, SCYNEXIS demonstrated that the hepatitis C virus required multiple mutations across two separate proteins in order to establish resistance to SCY-635. The majority of HCV drugs on the market and in development require only one targeted viral mutation to establish resistance.

16 Apr 2010

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects.

16 Apr 2010

Scientists grow cultured neurons to investigate basic mechanisms of memory

In order to be able to understand complex organs such as the brain or the nervous system, simplified model systems are required. A group of scientists led by the Frankfurt brain researcher Erin Schuman has successfully developed a novel method to grow cultured neurons in order to investigate basic mechanisms of memory.

16 Apr 2010

DNA modification can define early onset glioblastoma

A class of brain tumor that tends to emerge in younger patients but is less aggressive than others can be identified by examining DNA methylation of a specific set of genes, scientists at The University of Texas M. D. Anderson Cancer Center and colleagues with The Cancer Genome Atlas report today online at Cancer Cell.

16 Apr 2010

RUCDR is poised to become a world leader in human disease and genome studies

Despite the continuing, crippling effects of a nationwide recession, a genetics research laboratory on Rutgers' Busch Campus is experiencing an economic boom.

16 Apr 2010

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

CombinatoRx, Incorporated today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

16 Apr 2010

Cell News and Research

MiRNA-21 interferes with Herceptin therapy, says study

Marker found in iPS cells correlates with levels of pluripotency: Researchers

New drug to stop the growth of prostate cancer tumors investigated

Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH

Treatment with high dose UDCA no more effective for NASH: German study

Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

Research reveals TRPV3 protein as potential new drug target for cancer and skin disorders

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Pharmacyclics to present on Btk and HDAC programs at AACR 2010

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

New study may help devise better treatment strategies for cancer and heart disease

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Scientists grow cultured neurons to investigate basic mechanisms of memory

DNA modification can define early onset glioblastoma

RUCDR is poised to become a world leader in human disease and genome studies

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

Improve fermentation and cell culture performance with real-time gas analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics